Jointly provided by Postgraduate Institute for Medicine, the National Eczema Association and Impact Education, LLC.
|
This activity is supported by independent educational grants from Sanofi and Regeneron Pharmaceuticals, Pfizer, Inc. and Incyte Corporation.
|
These live webcasts are now complete!
An on-demand CE archive is coming soon.
Until then, please visit www.impactedu.net for more free CE activities.
|
|
Learn About
|
- The clinical, economic, and humanistic burden of AD
- Data from recently approved and emerging AD therapies
- Benefits of multidisciplinary care in AD patients
|
Expert Faculty Presenters
|
|
|
Edmund Pezalla, MD, PhD, MPH (June 2 only)
CEO
Enlightenment Bioconsult, LLC
|
|
Michele Guadalupe, MPH
Associate Director, Advocacy & Access
National Eczema Association
|
|
Peter Lio, MD
Clinical Assistant Professor of Dermatology and Pediatrics
Northwestern University Feinberg School of Medicine
Founding Director
Chicago Integrative Eczema Center
|
|
Michael Zeglinski, RPh (May 16 only)
Former SVP & CEO
Optum Specialty & Infusion Pharmacies
|
|
Terry Richardson, PharmD, BCACP
(June 2 only)
Vice President, Education Strategy and Development
Impact Education, LLC
|
|
|
|
|
Who Should Attend?
|
The primary target audience for this initiative consists of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
|
|
Statement of Need/Program Overview
|
Novel treatments and management strategies have the potential to target the underlying pathology resulting in decreased clinical and economic burden for the patient and health care system. However, managed care pharmacists and other payer professionals can lack knowledge of the clinical, economic, and humanistic burden of atopic dermatitis (AD) which can empower them to enact health care benefit policy strategies to reduce the disease burden and enhance the potential for optimal treatment outcomes.
|
|
Educational Objectives
|
At the conclusion of this activity, participants should be able to demonstrate improved ability to:
- Explore the spectrum of clinical, economic, and humanistic burden of AD
- Review clinical data from recently approved and emerging AD therapies
- Evaluate benefit design strategies that can contribute to appropriate access and utilization, while simultaneously managing costs and improving treatment outcomes
- Assess the benefits of multidisciplinary care in AD patients
|
|
Agenda
|
Opening Comments
Michael Zeglinski, RPh (May 16 webcast)
Terry Richardson, PharmD, BCACP (June 2 webcast)
|
Clinical Update on the Evolving AD Treatment Paradigm
Peter Lio, MD
|
Evidenced-based Decision Making in a Cost Conscience Environment
Michael Zeglinski, RPh (May 16 webcast)
Edmund Pezalla, MD, PhD, MPH (June 2 webcast)
|
Medical and Pharmacy Management Strategies to Enhance AD Patient Outcomes (case-based discussion)
Terry Richardson, PharmD, BCACP
|
|
Audience Q&A Session
|
Key Takeaways and Closing Comments
|
|
Accreditation Information
|
|
Joint Accreditation Statement |
 |
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, Impact Education, LLC and the National Eczema Association. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
|
|
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
|
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008162-9999-22-181-L01-P
Type of Activity: Knowledge
Please note: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.
|
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.
|
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.
Fee Information
No additional fee is required to attend this CPE/CME activity.
If you have any questions, please call (215) 619-8812 or email info@impactedu.net.
|
|
